ArticleClinical, cosmetic and investigational dermatology2026
Successful Treatment of Linear Porokeratosis with Ivarmacitinib in an Adolescent: A Case Report.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porokeratosis is a rare cutaneous disorder of keratinization, and its linear variant typically follows the lines of Blaschko. We report a case of a 15-year-old female patient with a 3-year history of a linear eruption on her right waist and thigh, accompanied by severe pruritus. Previous interventions, including topical corticosteroids, antihistamines, and oral prednisone, had failed to produce clinical improvement. The diagnosis of linear porokeratosis was confirmed after histopathological examination revealed the characteristic cornoid lamella. The patient was prescribed ivarmacitinib at a dose of 4 mg once daily. At the 3-month follow-up, the patient reported a significant reduction in pruritus, and clinical examination showed marked flattening of the papules, with no adverse events reported. Ivarmacitinib is a highly selective JAK1 inhibitor, and JAK1 plays a crucial role in the pathogenesis of inflammatory diseases. Ivarmacitinib was successfully utilized for the first time in the treatment of an adolescent patient with linear porokeratosis. Although the precise mechanism by which ivarmacitinib addresses linear porokeratosis has yet to be definitively elucidated, this case provides clinicians with a novel perspective and an additional option regarding pharmacological selection and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.